Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2024
Reporting Period: Events occurring through November 19, 2024, with a disclosure dated November 20, 2024.
Key Financial Metrics
This filing reports on capital raising activities rather than operational financial performance. The filing text does not provide data on revenue, profit, cash flow, margins, or debt levels.
| Metric | Value |
|---|---|
| Total Net Proceeds (ATM) | $250,802 |
| Total Gross Proceeds (Estimated) | $258,558 |
| Total Commissions Paid | $7,756 |
| Total Shares Issued (ATM) | 154,282 |
Material Changes and Events
- Capital Raising (Item 8.01): The Company executed sales under its At The Market (ATM) Offering Agreement with Ladenburg Thalmann & Co. Inc.
- Period 1 (Sept 18 - Sept 30, 2024): Issued 17,167 shares; raised $34,511 net of $1,067 in commissions.
- Period 2 (Oct 1 - Nov 19, 2024): Issued 137,115 shares; raised $216,291 net of $6,689 in commissions.
- Regulatory Disclosure (Item 7.01): On November 20, 2024, the Company released a video detailing initial results from its Pharmacokinetic (PK) study, a requirement for an FDA 510(k) submission.
Guidance, Outlook, and Risks
Outlook: The release of PK study results indicates progress toward an FDA 510(k) submission, a critical milestone for product commercialization. The successful execution of the ATM offering demonstrates the Company's ability to access capital markets for liquidity.
Risks and Contingencies: The filing does not explicitly list new risks. However, reliance on ATM offerings suggests ongoing liquidity needs. The success of the business model remains contingent on the FDA approval process following the PK study.
Investor Verification Checklist
- Verify the specific details of the Pharmacokinetic (PK) study results via the video link provided on the Company's website.
- Confirm the remaining capacity under the ATM Offering Agreement with Ladenburg Thalmann & Co. Inc.
- Review the Company's cash burn rate and runway given the recent capital raise of approximately $250,000.
- Monitor subsequent filings for the formal submission of the FDA 510(k) application.